The ability of F+D to induce an inflamed TME and upregulate PD-1, both highly predictive factors for sensitivity to anti-PD-1 agents [15,16], makes F+D an attractive regimen to administer in KRAS+/ER+ lung cancer prior to an ICB. The gene discussed is KRAS; the disease is lung cancer.